Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Travere Therapeutics Inc shares valued at $589,101 were sold by LYONS GARY A on Oct 04 ’24. At $14.73 per share, LYONS GARY A sold 40,000 shares. The insider’s holdings dropped to 51,000 shares worth approximately $0.93 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, GARY A LYONS purchased 40,000 shares, netting a total of over 546,000 in proceeds.
Before that, Meckler Jeffrey A had sold 40,000 shares from its account. In a trade valued at $562,324, the Director traded Travere Therapeutics Inc shares for $14.06 each. Upon closing the transaction, the insider’s holdings decreased to 40,000 shares, worth approximately $1.48 million.
As published in their initiating research note from Scotiabank on October 16, 2024, Travere Therapeutics Inc [TVTX] has been a Sector outperform. Analysts at Guggenheim upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in early September. As of March 27, 2024, Guggenheim has decreased its “Buy” rating to a “Neutral” for TVTX. Earlier on December 05, 2023, Citigroup upgraded its rating. Their new recommendation was “a Buy” for TVTX stock which previously was a “a Neutral”.
Analyzing TVTX Stock Performance
During the last five days, there has been a surge of approximately 6.66%. Over the course of the year, Travere Therapeutics Inc shares have jumped approximately 103.00%. Shares of the company reached a 52-week high of $18.82 on 10/17/24 and a 52-week low of $5.12 on 04/25/24. A 50-day SMA is recorded $12.50, while a 200-day SMA reached $9.03. Nevertheless, trading volume fell to 1.02 million shares from 1.11 million shares the previous day.
Support And Resistance Levels for Travere Therapeutics Inc (TVTX)
According to the 24-hour chart, there is a support level at 17.73, which, if violated, would cause prices to drop to 17.22. In the upper region, resistance lies at 18.79. The next price resistance is at 19.34. RSI (Relative Strength Index) is 74.30 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 2.02, which suggests the price will increase in the coming days. Percent R is at 10.22%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
